Interventions to Address Medical Conditions and Health-Risk Behaviors among Persons with Serious Mental Illness: A Comprehensive Review

Schizophrenia Bulletin

Volumn 42, Issue 1, 2016, Pages 96-124

  McGinty, Emma E ^a   Baller, Julia ^a   Azrin, Susan T ^b   Juliano Bult, Denise ^b   Daumit, Gail L ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

intervention; medical; obesity; schizophrenia; somatic; tobacco

Indexed keywords

AMFEBUTAMONE; VARENICLINE; ANTIDIABETIC AGENT; DOPAMINE UPTAKE INHIBITOR; METFORMIN; NICOTINIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; HEALTH BEHAVIOR; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; MAJOR DEPRESSION; MENTAL DISEASE; OBESITY; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SMOKING; VIRUS HEPATITIS; WEIGHT REDUCTION; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASES; COMPLICATION; HIV INFECTIONS; HYPERLIPIDEMIAS; MOTOR ACTIVITY; OVERWEIGHT; PROCEDURES; RISK REDUCTION; SMOKING CESSATION;

BEHAVIOR THERAPY; BIPOLAR DISORDER; BUPROPION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DOPAMINE UPTAKE INHIBITORS; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; METFORMIN; MOTOR ACTIVITY; NICOTINIC AGONISTS; OBESITY; OVERWEIGHT; RISK REDUCTION BEHAVIOR; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; VARENICLINE;

EID: 84954358010     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv101     Document Type: Review

References (191)

1. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:1-14.
2. Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368:1594-1602.
3. Druss BG, Zhao L, Von Esenwein S, Morrato EH, Marcus SC. Understanding excess mortality in persons with mental illness: 17-year follow up of a nationally representative US survey. Med Care. 2011;49:599-604.
4. Allison DB, Newcomer JW, Dunn AL, et al. Obesity among those with mental disorders: A National Institute of Mental Health meeting report. Am J Prev Med. 2009;36:341-350.
5. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
6. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006;67(suppl 9):25-30; discussion 36-42.
7. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298:1794-1796.
8. McGinty EE, Daumit GL. Epidemiology of obesity. Psychiatr Ann. 2011;41:484-488.
9. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: A costeffectiveness analysis. J Eval Clin Pract. 2010;16:744-755.
10. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273-281.
11. Henderson DC, Borba CP, Daley TB, et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry. 2006;18:99-105.
12. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry. 2003;183:534-539.
13. Osborn DP, Nazareth I, King MB. Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness: A cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol. 2007;42:787-793.
14. Berkman A. Reducing sexual risk behaviors of men with severe mental illness. Psychiatr Serv. 2006;57:417.
15. Daumit GL, Goldberg RW, Anthony C, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 2005;193:641-646.
16. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventive perspective. Harv Rev Psychiatry. 2006;14:212-222.
17. Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J. Tobacco smoking behaviors in bipolar disorder: A comparison of the general population, schizophrenia, and major depression. Bipolar Disord. 2009;11:154-165.
18. Baillargeon JG, Paar DP, Wu H, et al. Psychiatric disorders, HIV infection and HIV/hepatitis co-infection in the correctional setting. AIDS Care. 2008;20:124-129.
19. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91:31-37.
20. Bartels S, Desilets R. Health Propotion Programs for People with Serious Mental Illness (Prepared by the Dartmouth Health Promotion Research Team). Washington, DC: SAMHSA-HRSA Center for Integrated Health Solutions; 2012.
21. Gierisch J, Nieuwsma J, Bradford D, et al. Interventions to Improve Cardiovascular Risk Factors in People with Serious Mental Illness. Comparative Effectiveness Review No. 105. AHRQ Publication No. 13-EHC063-EF. Rockville, MD: Agency for Health Care Research and Quality; 2013
22. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006;18:23-31.
23. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140:159-168.
24. Verhaeghe N, Maeseneer JD, Maes L, Heeringen CV, Annemans L. Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: A systematic review. Int J Behav Nutr Phys Act. 2011;8:1-12.
25. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and metaanalysis. Neuropsychopharmacology. 2010;35:1520-1530.
26. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101-107.
27. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007;1:CD005148.
28. Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2010;196:346-353.
29. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010;6:CD007253.
30. Owens D, Lohr K, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions. In: Methods Guide for Comparative Effectiveness Reviews [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2009. http://effectivehealthcare.ahrq.gov/health-Info.cfm?infotype=rr&ProcessID=60.
31. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2:31-49.
32. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophr Res. 2006;86:36-44.
33. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv. 2007;58:544-550.
34. Alvarez-Jiménez M, Martínez-García O, Pérez-Iglesias R, Ramírez ML, Vázquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res. 2010;116:16-19.
35. Cordes J, Thünker J, Regenbrecht G, et al. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four-and 48-week results from a 6-month randomized trial. World J Biol Psychiatry. 2011;15:229-241.
36. Milano W, Grillo F, Del Mastro A, et al. Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study. Adv Ther. 2007;24:123-134.
37. Marzolini S, Jensen B, Melville P. Feasibility and effects of a group-based resistance and aerobic exercise program for individuals with severe schizophrenia: A multidisciplinary approach. Mental Health and Phys Act. 2009;2:29-36.
38. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: A randomized controlled trial. Aust N Z J Psychiatry. 2005;39:479-486.
39. Gillhoff K, Gaab J, Emini L, Maroni C, Tholuck J, Greil W. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder: A randomized controlled trial. Prim Care Companion J Clin Psychiatry. 2010;12. doi:10.4088/PCC.09m00906yel.
40. Methapatara W, Srisurapanont M. Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: A 12-week, randomized, controlled trial. Psychiatry Clin Neurosci. 2011;65:374-380.
41. Forsberg KA, Björkman T, Sandman PO, Sandlund M. Physical health-A cluster randomized controlled lifestyle intervention among persons with a psychiatric disability and their staff. Nord J Psychiatry. 2008;62:486-495.
42. Kwon JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapinetreated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry. 2006;67:547-553.
43. Cordes J, Thünker J, Regenbrecht G, et al. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four-and 48-week results from a 6-month randomized trial. World J Biol Psychiatry. 2014;15:229-241.
44. Scheewe TW, Backx FJ, Takken T, et al. Exercise therapy improves mental and physical health in schizophrenia: A randomised controlled trial. Acta Psychiatr Scand. 2013;127:464-473.
45. Bartels SJ, Pratt SI, Aschbrenner KA, et al. Clinically significant improved fitness and weight loss among overweight persons with serious mental illness. Psychiatr Serv. 2013;64:729-736.
46. Lovell K, Wearden A, Bradshaw T, et al. An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: The INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study. J Clin Psychiatry. 2014;75:498-505.
47. Kilbourne AM, Goodrich DE, Lai Z, Clogston J, Waxmonsky J, Bauer MS. Life Goals Collaborative Care for patients with bipolar disorder and cardiovascular disease risk. Psychiatr Serv. 2012;63:1234-1238.
48. Attux C, Martini LC, Elkis H, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry. 2013;13:60.
49. Usher K, Park T, Foster K, Buettner P. A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. J Adv Nurs. 2013;69:1539-1548.
50. Kalarchian MA, Marcus MD, Levine MD, et al. Behavioral treatment of obesity in patients taking antipsychotic medications. J Clin Psychiatry. 2005;66:1058-1063.
51. Smith S, Yeomans D, Bushe CJ, et al. A well-being programme in severe mental illness. Baseline findings in a UK cohort. Int J Clin Pract. 2007;61:1971-1978.
52. Daumit GL, Dalcin AT, Jerome GJ, et al. A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. Int J Obes (Lond). 2011;35:1114-1123.
53. Baker A, Richmond R, Castle D, et al. Coronary heart disease risk reduction intervention among overweight smokers with a psychotic disorder: pilot trial. Aust N Z J Psychiatry. 2009;43:129-135.
54. Attux C, Martini LC, Araújo CM, Roma AM, Reis AF, Bressan RA. The effectiveness of a non-pharmacological intervention for weight gain management in severe mental disorders: results from a national multicentric study. Rev Bras Psiquiatr. 2011;33:117-121.
55. Mangurian C, Chaudhry S, Capitelli L, et al. Implementation of a weight loss program for Latino outpatients with severe mental illness. Community Ment Health J. 2013;49:150-156.
56. Skrinar GS, Huxley NA, Hutchinson DS, Menninger E, Glew P. The role of a fitness intervention on people with serious psychiatric disabilities. Psychiatr Rehabil J. 2005;29:122-127.
57. Niv N, Cohen AN, Hamilton A, Reist C, Young AS. Effectiveness of a psychosocial weight management program for individuals with schizophrenia. J Behav Health Serv Res. 2014;41:370-380.
58. Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41:980-989.
59. Kuo FC, Lee CH, Hsieh CH, Kuo P, Chen YC, Hung YJ. Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obese non-diabetic patients with schizophrenia. Psychiatry Res. 2013;209:150-154.
60. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66:205-212.
61. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh. 2003;35:237-241.
62. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008;41:17-23.
63. Brown C, Goetz J, Hamera E. Weight loss intervention for people with serious mental illness: A randomized controlled trial of the RENEW program. Psychiatr Serv. 2011;62:800-802.
64. Gelkopf M, Noam S, Rudinski D, et al. Nonmedication smoking reduction program for inpatients with chronic schizophrenia: A randomized control design study. J Nerv Ment Dis. 2012;200:142-146.
65. Goldberg RW, Reeves G, Tapscott S, et al. "MOVE!" Outcomes of a weight loss program modified for veterans with serious mental illness. Psychiatr Serv. 2014;64:737-744.
66. Voruganti LN, Whatham J, Bard E, et al. Going beyond: an adventure-and recreation-based group intervention promotes well-being and weight loss in schizophrenia. Can J Psychiatry. 2006;51:575-580.
67. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol. 2005;20:447-448.
68. Bushe CJ, McNamara D, Haley C, McCrossan MF, Devitt P. Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry. 2008;8:76.
69. Chen CK, Chen YC, Huang YS. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: A 12-month follow up. Psychiatry Clin Neurosci. 2009;63:17-22.
70. Porsdal V, Beal C, Kleivenes OK, et al. The Scandinavian Solutions for Wellness study-A two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry. 2010;10:42.
71. Temmingh H, Claassen A, van Zyl S, et al. The evaluation of a telephonic wellness coaching intervention for weight reduction and wellness improvement in a community-based cohort of persons with serious mental illness. J Nerv Ment Dis. 2013;201:977-986.
72. Zhang JP, Weiss JJ, McCardle M, et al. Effectiveness of a cognitive behavioral weight management intervention in obese patients with psychotic disorders compared to patients with nonpsychotic disorders or no psychiatric disorders: results from a 12-month, real-world study. J Clin Psychopharmacol. 2012;32:458-464.
73. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebocontrolled study. Am J Psychiatry. 2008;165:352-358.
74. Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: A 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013;74:e424-e430.
75. Jarskog LF, Hamer RM, Catellier DJ, et al; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170:1032-1040.
76. Wu R-R, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2014;169:813-821.
77. Carrizo E, Fernández V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113:19-26.
78. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163:2072-2079.
79. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA. 2008;299:185-193.
80. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744-1746.
81. Bahk WM, Lee KU, Chae JH, Pae CU, Jun T, Kim KS. Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci. 2004;58:163-167.
82. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapineinduced weight gain. Hum Psychopharmacol. 2004;19:37-40.
83. Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacol. 2011;31:653-658.
84. Ranjbar F, Ghanepour A, Sadeghi-Bazargani H, Asadlo M, Alizadeh A. The effect of ranitidine on olanzapine-induced weight gain. Biomed Res Int. 2013;2013:639391.
85. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:297-302.
86. Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011;31:86-91.
87. Baptista T, Rangel N, El Fakih Y, et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: A pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry. 2009;42:14-19.
88. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115:101-105.
89. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28:169-175.
90. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: A randomised, doubleblind, placebo-controlled clinical trial. J Psychopharmacol. 2009;23:157-162.
91. Khazaal Y, Chatton A, Rusca M, Preisig M, Zullino D. Long-term topiramate treatment of psychotropic druginduced weight gain: A retrospective chart review. Gen Hosp Psychiatry. 2007;29:446-449.
92. McElroy SL, Winstanley E, Mori N, et al. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012;32:165-172.
93. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15:13-21.
94. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003;28:527-529.
95. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapineinduced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159:1058-1060.
96. Assuncao SS, Ruschel SI, Rosa Lde C, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr. 2006;28:270-276.
97. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: A double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13:81-85.
98. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapineor olanzapine-treated patients with overweight or obesity: A 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:706-711.
99. Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: A 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011;72:326-330.
100. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry. 2002;63:345-348.
101. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:297-302.
102. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115:101-105.
103. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: A random, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25:211-217.
104. Maki M, Bjorklund P. Improving cardiovascular disease screening in community mental health centers. Perspect Psychiatr Care. 2013;49:179-186.
105. Harrison MR, McMillan CF, Dickinson T. Service innovation: A comparison of two approaches for physical screening of psychiatric inpatients. Int J Psychiatry Clin Pract. 2012;16:157-160.
106. Wiechers IR, Viron M, Stoklosa J, Freudenreich O, Henderson DC, Weiss A. Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic. Acad Psychiatry. 2012;36:118-121.
107. Osborn DP, Nazareth I, Wright CA, King MB. Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phasetwo cluster randomised feasibility trial of community mental health teams. BMC Health Serv Res. 2010;10:61.
108. Bobes J, Alegría AA, Saiz-Gonzalez MD, Barber I, Pérez JL, Saiz-Ruiz J. Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Eur Psychiatry. 2011;26:305-312.
109. Thompson A, Hetrick SE, Alvarez-Jiménez M, et al. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Aust N Z J Psychiatry. 2011;45:740-748.
110. O'Callaghan C, Liew AYL, Yusof MSD, et al. Screening for metabolic syndrome in long-term psychiatric illness: Audit of patients receiving depot antipsychotic medication at a psychiatry clinic. Eur J Psychiatry. 2011;25:213-222.
111. Barnes TR, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatr Scand. 2008;118:26-33.
112. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218-225.
113. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53-61.
114. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218-225.
115. Evins AE, Cather C, Culhane MA, et al. A 12-week doubleblind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380-386.
116. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004;65:307-311; quiz 452-303.
117. Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: A randomized clinical trial. JAMA. 2014;311:145-154.
118. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934-1942.
119. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3:397-403.
120. Weiner E, Ball MP, Buchholz AS, et al. Bupropion sustained release added to group support for smoking cessation in schizophrenia: A new randomized trial and a meta-analysis. J Clin Psychiatry. 2012;73:95-102.
121. George TP, Vessicchio JC, Sacco KA, et al. A placebocontrolled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092-1096.
122. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835-1842.
123. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:654-660.
124. Dixon LB, Medoff D, Goldberg R, et al. Is implementation of the 5 A's of smoking cessation at community mental health centers effective for reduction of smoking by patients with serious mental illness? Am J Addict. 2009;18:386-392.
125. Robson D, Cole F, Jalasi S, et al. Smoking cessation and serious mental illness: A service evaluation of a drop-in stop smoking clinic on an acute in-patient unit. J Clin Nurs. 2013;22:405-413.
126. McClure JB, Swan GE, Catz SL, et al. Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat. 2010;38:394-402.
127. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl). 2011;217:279-287.
128. Kelly DL, McMahon RP, Weiner E, et al. Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. Schizophr Res. 2008;103:161-168.
129. Gallagher SM, Penn PE, Schindler E, Layne W. A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs. 2007;39:487-497.
130. Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH. Motivational interviewing with personalized feedback: A brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol. 2004;72:723-728.
131. Heggelund J, Nilsberg GE, Hoff J, Morken G, Helgerud J. Effects of high aerobic intensity training in patients with schizophrenia: A controlled trial. Nord J Psychiatry. 2011;65:269-275.
132. De Hert M, Kalnicka D, van Winkel R, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2006;67:1889-1896.
133. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. Schizophr Res. 2006;86:36-44.
134. Smith RC, Jin H, Li C, et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study. Schizophr Res. 2013;143:18-24.
135. Amrami-Weizman A, Maayan R, Gil-Ad I, et al. The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. Psychopharmacology (Berl). 2013;230:23-27.
136. Binford SH, Johnson MD, Kennedy RS, Leffler JB. Clinician education improves lipid monitoring in patients taking second-generation antipsychotic agents, nationally and locally. Health Outcomes Research in Medicine. 2012.
137. Chiverton P, Lindley P, Tortoretti DM, Plum KC. Well balanced: 8 steps to wellness for adults with mental illness and diabetes. J Psychosoc Nurs Ment Health Serv. 2007;45:46-55.
138. Nicol GE, Morrato EH, Johnson MC, et al. Best practices: implementation of a glucose screening program based on diffusion of innovation theory methods. Psychiatr Serv. 2011;62:12-14.
139. Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM. A randomized trial of medical care management for community mental health settings: The Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry. 2010;167:151-159.
140. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346:393-403.
141. Blank MB, Hanrahan NP, Fishbein M, et al. A randomized trial of a nursing intervention for HIV disease management among persons with serious mental illness. Psychiatr Serv. 2011;62:1318-1324.
142. Blank MB, Hennessy M, Eisenberg MM. Increasing quality of life and reducing HIV burden: The PATH+ intervention. AIDS Behav. 2014;18:716-725.
143. Rosenberg SD, Goldberg RW, Dixon LB, et al. Assessing the STIRR model of best practices for blood-borne infections of clients with severe mental illness. Psychiatr Serv. 2010;61:885-891.
144. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006;18:23-31.
145. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140:159-168.
146. Gierisch JM, Nieuwsma JA, Bradford DW, et al. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: A systematic review and meta-analysis. J Clin Psychiatry. 2014;75:e424-e440.
147. Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: A systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377-382.
148. Niv N, Cohen AN, Hamilton A, Reist C, Young AS. Effectiveness of a psychosocial weight management program for individuals with schizophrenia. J Behav Health Serv Res. 2012:1-10.
149. McLean N, Griffin S, Toney K, Hardeman W. Family involvement in weight control, weight maintenance and weight-loss interventions: A systematic review of randomised trials. Int J Obes Relat Metab Disord. 2003;27:987-1005.
150. Gallagher R, Armari E, White H, Hollams D. Multicomponent weight-loss interventions for people with cardiovascular disease and/or type 2 diabetes mellitus: A systematic review. Eur J Cardiovasc Nurs. 2013;12:320-329.
151. Felix HC, West DS. Effectiveness of weight loss interventions for obese older adults. Am J Health Promot. 2013;27:191-199.
152. Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: A systematic review of the literature. J Am Diet Assoc. 2011;111:92-102.
153. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36:71-93.
154. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;2:CD007253.
155. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013;170:1460-1467.
156. Evins AE. Reassessing the safety of varenicline. Am J Psychiatry. 2013;170:1385-1387.
157. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311:193-194.
158. Appel LJ, Clark JM, Yeh HC, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med. 2011;365:1959-1968.
159. Elmer PJ, Obarzanek E, Vollmer WM, et al; PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med. 2006;144:485-495.
160. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weightloss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859-873.
161. Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med. 2011;365:1969-1979.
162. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA. 1998;279:839-846.
163. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
164. Stamler R, Stamler J, Gosch FC, et al. Primary prevention of hypertension by nutritional-hygienic means. Final report of a randomized, controlled trial. JAMA. 1989;262:1801-1807.
165. Stevens VJ, Obarzanek E, Cook NR, et al; Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134:1-11.
166. Outcalt SD, Kroenke K, Krebs EE, et al. Chronic pain and comorbid mental health conditions: independent associations of posttraumatic stress disorder and depression with pain, disability, and quality of life. J Behav Med. 2015;38:535-543.
167. Gupta MA, Simpson FC. Obstructive sleep apnea and psychiatric disorders: A systematic review. J Clin Sleep Med. 2015;11:165-175.
168. Fishbain DA, Gao J, Lewis JE, Bruns D, Meyer LJ, Disorbio JM. Prevalence comparisons of somatic and psychiatric symptoms between community nonpatients without pain, acute pain patients, and chronic pain patients. Pain Med. 2015;16:37-50.
169. Yarlagadda A, Kaushik S, Clayton AH. Obstructive sleep apnea, hypoxia, and metabolic syndrome in psychiatric and nonpsychiatric settings. Psychiatry (Edgmont). 2008;5:48-50.
170. Goodson NJ, Smith BH, Hocking LJ, et al; Generation Scotland. Cardiovascular risk factors associated with the metabolic syndrome are more prevalent in people reporting chronic pain: results from a cross-sectional general population study. Pain. 2013;154:1595-1602.
171. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension. 2003;42:1067-1074.
172. Marcus JA, Pothineni A, Marcus CZ, Bisognano JD. The role of obesity and obstructive sleep apnea in the pathogenesis and treatment of resistant hypertension. Curr Hypertens Rep. 2014;16:411.
173. Filozof C, Fernández Pinilla MC, Fernández-Cruz A. Smoking cessation and weight gain. Obes Rev. 2004;5:95-103.
174. Druss BG, Zhao L, von Esenwein SA, et al. The Health and Recovery Peer (HARP) Program: A peer-led intervention to improve medical self-management for persons with serious mental illness. Schizophr Res. 2010;118:264-270.
175. Cook JA, Steigman P, Pickett S, et al. Randomized controlled trial of peer-led recovery education using Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES). Schizophr Res. 2012;136:36-42.
176. Casalino L, Gillies RR, Shortell SM, et al. External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases. JAMA. 2003;289:434-441.
177. Marchibroda JM. The impact of health information technology on collaborative chronic care management. J Manag Care Pharm. 2008;14:S3-11.
178. Bates DW, Bitton A. The future of health information technology in the patient-centered medical home. Health Aff (Millwood). 2010;29:614-621.
179. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-126.
180. McGinty EE, Baller J, Azrin ST, Juliano-Bult D, Daumit GL. Quality of medical care for persons with serious mental illness: A comprehensive review. Schizophr Res. 2015;165:227-235.
181. Bao Y, Casalino LP, Pincus HA. Behavioral health and health care reform models: patient-centered medical home, health home, and accountable care organization. J Behav Health Serv Res. 2013;40:121-132.
182. Barry CL, Huskamp HA. Moving beyond parity-mental health and addiction care under the ACA. N Engl J Med. 2011;365:973-975.
183. Druss BG, Mauer BJ. Health care reform and care at the behavioral health-primary care interface. Psychiatr Serv. 2010;61:1087-1092.
184. Centers for Medicare and Medicaid Services. Health Homes for Enrollees with Chronic Conditions. Baltimore, MD: Centers for Medicare and Medicaid Services. 2010.
185. Sandberg SF, Erikson C, Owen R, et al. Hennepin Health: A safety-net accountable care organization for the expanded Medicaid population. Health Aff (Millwood). 2014;33:1975-1984.
186. Desai MM, Rosenheck RA, Druss BG, Perlin JB. Mental disorders and quality of care among postacute myocardial infarction outpatients. J Nerv Ment Dis. 2002;190:51-53.
187. Petersen LA, Normand SL, Druss BG, Rosenheck RA. Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: are there disparities? Health Serv Res. 2003;38:41-63.
188. Kilbourne AM, Welsh D, McCarthy JF, Post EP, Blow FC. Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. J Gen Intern Med. 2008;23:1628-1633.
189. Kilbourne AM, Greenwald DE, Hermann RC, Charns MP, McCarthy JF, Yano EM. Financial incentives and accountability for integrated medical care in Department of Veterans Affairs mental health programs. Psychiatr Serv. 2010;61:38-44.
190. Kilbourne AM, Lai Z, Bowersox N, Pirraglia P, Bauer MS. Does colocated care improve access to cardiometabolic screening for patients with serious mental illness? Gen Hosp Psychiatry. 2011;33:634-636.
191. Druss BG. Improving medical care for persons with serious mental illness: challenges and solutions. J Clin Psychiatry. 2007;68(suppl 4):40-44.